HLB Pharma has reportedly applied to the Health Insurance Review and Assessment Service (HIRA) for reimbursement of 'Citrelin ODT,' a domestically distributed treatment for spinocerebellar degeneration.

This product was approved in South Korea in 2015, but it has been distributed to the Korean market as a non-reimbursed drug. However, with the successful completion of its recent Phase 4 trial, involving Korean patients, the company may now attempt to obtain reimbursement for the drug.

According to industry sources on December 16, the HIRA received an application for the reimbursement of Citrelin ODT and has begun its review.

Citrelin ODT 5mg (taltirelin) received approval